Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

Author:

Dowell Alexander C.ORCID,Butler Megan S.,Jinks Elizabeth,Tut Gokhan,Lancaster TaraORCID,Sylla Panagiota,Begum Jusnara,Bruton Rachel,Pearce HaydenORCID,Verma Kriti,Logan Nicola,Tyson GraceORCID,Spalkova Eliska,Margielewska-Davies Sandra,Taylor Graham S.ORCID,Syrimi Eleni,Baawuah Frances,Beckmann Joanne,Okike Ifeanyichukwu O.,Ahmad Shazaad,Garstang JoannaORCID,Brent Andrew J.,Brent Bernadette,Ireland Georgina,Aiano Felicity,Amin-Chowdhury Zahin,Jones Samuel,Borrow RayORCID,Linley EzraORCID,Wright John,Azad Rafaq,Waiblinger Dagmar,Davis Chris,Thomson Emma C.ORCID,Palmarini Massimo,Willett Brian J.ORCID,Barclay Wendy S.,Poh JohnORCID,Amirthalingam Gayatri,Brown Kevin E.,Ramsay Mary E.ORCID,Zuo JianminORCID,Moss PaulORCID,Ladhani Shamez

Abstract

AbstractSARS-CoV-2 infection is generally mild or asymptomatic in children but a biological basis for this outcome is unclear. Here we compare antibody and cellular immunity in children (aged 3–11 years) and adults. Antibody responses against spike protein were high in children and seroconversion boosted responses against seasonal Beta-coronaviruses through cross-recognition of the S2 domain. Neutralization of viral variants was comparable between children and adults. Spike-specific T cell responses were more than twice as high in children and were also detected in many seronegative children, indicating pre-existing cross-reactive responses to seasonal coronaviruses. Importantly, children retained antibody and cellular responses 6 months after infection, whereas relative waning occurred in adults. Spike-specific responses were also broadly stable beyond 12 months. Therefore, children generate robust, cross-reactive and sustained immune responses to SARS-CoV-2 with focused specificity for the spike protein. These findings provide insight into the relative clinical protection that occurs in most children and might help to guide the design of pediatric vaccination regimens.

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3